We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Inspire Medical Systems Inc | NYSE:INSP | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 243.61 | 0 | 09:05:48 |
From Apr 2022 to Apr 2024
By Dean Seal
Inspire Medical Systems Inc. said the Food and Drug Administration has granted approval for the use of full-body magnetic resonance imaging scans in conjunction with its sleep apnea therapy.
The Golden Valley, Minn.-based company, which develops treatments for patients with obstructive sleep apnea, previously had approval to use MRI scans for only the head, neck and extremities.
The expansion to full-body capabilities is retroactive, meaning it will apply to all patients that already have the company's Inspire IV neurostimulator device in place.
"Providing the full range of scan options enables us to better help all current and future patients with their imaging needs," Chief Executive Tim Herbert said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
July 06, 2022 08:42 ET (12:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Inspire Medical Systems Chart |
1 Month Inspire Medical Systems Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
